Canada renews commitment to fight breast cancer:
This article was originally published in Clinica
Executive Summary
The Canadian government has made Can$45 million ($32 million) available to renew the Canadian Breast Cancer Initiative (CBCI), which was first launched in 1993. The funding includes Can$10 million from the Medical Research Council of Canada for the research arm of the CBCI. Health Canada is also allocating Can$20 million over the next five years to areas including early detection and quality screening for breast cancer. Breast cancer is the most common cancer diagnosed in Canadian women. It is estimated that 5,300 women will die of the disease this year and there will be 19,300 new cases.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.